Celltrion, Inc. (068270.KS)
Celltrion, Inc.
23 Academy-ro
Yeonsu-gu
Incheon
South Korea
82 3 2850 5000
https://www.celltrion.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo:
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Hyong-Gi Kim | CEO & Internal Director | N/D | N/D | 1965 |
| Mr. Woo-Sung Kee | CEO & Internal Director | N/D | N/D | 1961 |
| Jin-seok Seo | Co-CEO & Inside Co-Chairman of the Board | N/D | N/D | N/D |
| Mr. Stephen Yeum | Founder | N/D | N/D | N/D |
| Mr. Min-Cheol Shin | Director of Finance | N/D | N/D | 1971 |
| Mr. Ji-Hoon Choi | Director of Legal Affairs | N/D | N/D | 1971 |
Descripción
Celltrion, Inc., together with its subsidiaries, develops and produces drugs based on proteins for the treatment of oncology in South Korea. The company markets bio pharmaceuticals; generic pharmaceuticals; and covid-19 test kits. Its antibody biosimilar pipeline includes CT-P39 that is in phase 3 clinical trial for the treatment of asthma and urticaria; CT-P41, which is in phase 3 clinical trial for the treatment of osteoporosis and bone loss; CT-P42, which is in phase 3 clinical trial for the treatment of diabetic macular edema; and CT-P43 that is in phase 3 clinical trial for the treatment of psoriasis, crohn's disease, and ulcerative colitis. The company also offers CT-P47, which is in phase 3 clinical trial for the treatment of rheumatoid arthritis; and CT-P53 that is is in phase 3 clinical trial for the treatment of multiple sclerosis. Celltrion, Inc. was founded in 2002 and is headquartered in Incheon, South Korea.
Gestión corporativa
La calificación ISS Governance QuickScore de Celltrion, Inc. a partir del 1 de junio de 2024 es 3. Las puntuaciones principales son Auditoría: 1; Junta: 4; Derechos del accionista: 4; Compensación: 1.
